Home > CH-FUBIATA.

Krotulski, Alex J and Shinefeld, Jennifer and Fogarty, Melissa F and DeBord, Joshua and Logan, Barry K (2022) CH-FUBIATA. Pennsylvania: Center for Forensic Science Research & Education.

[img]
Preview
PDF (CH-FUBIATA)
375kB

UPAC Name: N-cyclohexyl-2-[1-[(4-fluorophenyl)methyl]indol-3-yl]acetamide

CH-FUBIATA is classified as a synthetic cannabinoid. Synthetic cannabinoids have been reported to cause psychoactive effects similar to delta-9-tetrahydrocannabinol (THC). Synthetic cannabinoids have caused adverse events, including deaths, as described in the literature. Little to no information is currently known about the activity, potency, and/or toxicity of CH-FUBIATA. New synthetic cannabinoids continue to emerge among the recreation drug supply internationally, seemingly as replacements after a synthetic cannabinoid class-wide ban implemented by China in July 2021 which included most traditional indole and indazole structural scaffolds.1 Many of these new synthetic cannabinoid analogues are unstudied with pharmacological and human effects undetermined. Structurally similar synthetic cannabinoids include CH-PIATA (reported April 2022) and ADB-FUBIATA (reported November 2021); CH-FUBIATA was identified alongside ADB-FUBIATA in the sample reported. Currently, CH-FUBIATA and related analogues are not scheduled substances in the United States.

Item Type
Report
Publication Type
International, Report
Drug Type
New psychoactive substance
Intervention Type
Screening / Assessment
Date
21 June 2022
Pages
7 p.
Publisher
Center for Forensic Science Research & Education
Place of Publication
Pennsylvania
EndNote
Related (external) link

Repository Staff Only: item control page